foxo4-dri human trial 10mg FOXO4-DRI — ≥99% Purity, COA
Description
Choose Transparency
A novel octa-arginine-modified injectable self-assembling peptide hydrogel for multidrug-resistant cancer therapy
AbdelnourSAAbd El-HackMEAlagawanyMFaragMRElnesrSS
The information provided is for scientific and descriptive purposes only and does not constitute therapeutic guidance.
For example, the precise role of gene-environment interactions in the comorbidity of hypertension and lung cancer is not yet fully understood
